I nflammation often initiates by the recruitment of neutrophils and monocytes to the damaged tissue, a process normally rapidly terminated via, among others, the secretion of anti-inflammatory cytokines. An imbalance of inflammation initiation and arrest results in chronic inflammatory diseases, such as atherosclerosis, in which both innate and adaptive immune responses participate in response to risk factors, such as elevated lipoproteins. 1 In the mouse, 2 major types of monocytes, Ly6C hi and Ly6C low , circulate in blood. 2 Ly6C hi monocytes display a proinflammatory phenotype, whereas Ly6C low monocytes are patrolling cells monitoring vascular integrity and exerting, without extravasation, anti-inflammatory and tissue repair activities. Of note, hypercholesterolemia induces a predominant Ly6C hi monocytosis, which gives rise to atherosclerotic lesion macrophages. 3 Monocyte-derived macrophages are among the first immune cells detected in the developing atherosclerotic plaque. Recently, the macrophage population in human atherosclerotic plaques was also found to be heterogeneous 4 and classified as proinflammatory "classical" M1 or anti-inflammatory "alternative" M2 macrophages. M1 macrophages are typically found in lipid-rich areas with necrosis, characterizing the unstable plaque, whereas M2 macrophages are enriched in lipid-poor zones of high cellularity. 5 An imbalance in favor of the M1 phenotype could thus maintain a deleterious inflammatory state, whereas shifting toward the M2 phenotype would convey anti-inflammatory responses.
Nuclear receptors, such as the peroxisome proliferator-activated receptor (PPAR)␥ and PPAR␤/␦, favor M2 polarization, and their pharmacological activation reduces atherosclerosis, at least in murine models. 4,6 -8 Recent evidence also points to a role of NR4A orphan receptors in vascular biology and atherosclerosis. Nur77/NR4A1, Nurr1/NR4A2, and Nor1/NR4A3 constitute a subclass of the nuclear receptor gene superfamily. Unlike the PPARs, NR4A family members appear to act as ligand-independent transcription factors. Initially characterized as early response genes whose expression is induced by a variety of cellular signals and stresses such as antigen receptor ligation, membrane depolarization, NGF stimulation, and cAMP, 9 NR4A isotypes were shown to play critical roles in negative T-cell maturation, dopaminergic neuron differentiation, and early embryonic development. 10 More recent investigations have documented a role for NR4As in metabolic regulation and NR4A expression is regulated by metabolic signals such as glucose, glucagon, insulin, fasting, and ␤-adrenergic signaling in metabolically active tissues. 11 NR4As are also expressed and regulated by (patho)physiological stimuli in monocytes, T cells, macrophages, vascular smooth muscle cells (SMC), and endothelial cells. 12 Interestingly, Nur77 controls bone marrow differentiation and survival of Ly6C low monocytes, 13 whereas Nurr1 is necessary to confer Treg suppressive ability. 14 The cell-specific contribution of the NR4A isotypes to vascular remodeling has begun to be studied. Nur77 inhibits TNF-induced endothelial cell activation and U937 monocyte adhesion to endothelial HUVEC cells by decreasing the expression of cell adhesion molecules ICAM-1 and VCAM-1. 15 Nur77 and Nurr1 decrease smooth muscle cell proliferation, 16 -19 whereas Nor1 promotes vascular remodeling after injury, 20 endothelial cell monocyte adhesion, and atherosclerosis progression in ApoEϪ/Ϫ mice. 21 However, so far, the role of Nur77 in atherosclerosis has not yet been studied.
In the current issue of Circulation Research, 2 studies report on the role of Nur77 in atherosclerosis and the contribution of its expression in bone marrow-derived cells therein. 22 Although the molecular mechanisms were addressed in both studies, the results are not entirely clear and are, to a certain extent, controversial. Hanna et al show, as previously reported, 13 that Nur77-deficient mice display lower monocytosis due to a decrease in Ly6C low monocytes, which could lead to an imbalance of the Ly6C hi /LyC6 low ratio. However, Ly6C hi monocytes adhere similarly to endothelial cells, suggesting the existence of other mechanisms. Interestingly, Nur77 expression increases during differentiation of this monocyte subtype, suggesting a role for this nuclear receptor in the differentiating macrophage.
Extensive macrophage characterization studies were performed in both studies. Nur77-deficient Ly6C hi peritoneal and bone marrow-derived macrophages (BMM) displayed a proinflammatory phenotype, with activated NFB-signaling. Hence, although there is some inconsistency between both studies, Nur77-deficient macrophages present, at least in part, an M1 phenotype. These findings contrast with a previous study demonstrating that Nur77 potentiates the induction of inflammatory gene expression in response to LPS in macrophages, 24 possibly due to the different models and experimental approaches used. Hamers et al further observed an enhanced expression of stromal cell-derived factor (SDF)-1␣, which mediates chemo-attraction in conditioned medium from Nur77Ϫ/Ϫ BMM and may hence trigger the observed increases in macrophage and SMC content in atherosclerotic lesions. However, such effects on chemo-attraction were not found by Hanna et al, who in contrast to Hamers et al, found increased scavenger receptor expression both in Nur77Ϫ/Ϫ monocytes and macrophages as well as lipid accumulation, in line with previous results. 25 Finally, Nur77-deficient BMM showed altered expression levels of M2 markers, but the changes were not consistent and again were different between the 2 studies. Therefore, deletion of Nur77, both in the wild-type 23 and high-fat diet ApoEϪ/Ϫ 22 backgrounds, does not simply regulate M2 to M1 polarization.
The different experimental strategies might explain the distinct molecular mechanisms put forward in these 2 papers. Hanna et al pinned down the molecular basis of the increased atherosclerosis phenotype to an abnormally high constitutive activation of the NF-B pathway, whereas Hamers et al suggested that the mechanism be related to increased expression of SDF-1␣ and enhanced chemo-attraction. Clearly, further studies are required to delineate the exact function(s) of Nur77 in atherosclerosis. Moreover, whether Nur77 deficiency acts to (de)stabilize the plaque is unclear, since SMC content increased. Finally, the bone marrow transplantation procedure introduces not only cells of macrophage origin, but also all other cells of the hematopoietic lineage. Hence, the atherosclerosis phenotype may be in part due to actions of Nur77 in other cells, as illustrated by the increased plasma B lymphocyte count reported by Hamers et al, but not by Hanna et al.
NR4As exert multiple biological effects in both the cytoplasmic and nuclear compartments. Intriguingly, both cytoplasmic and nuclear actions of Nur77 rely at least in part on their interaction with retinoid X receptors, allowing shuttling of Nurr77 either to the mitochondria, where it exerts a proapoptotic activity, or to the nucleus, from which it controls gene expression after DNA binding. The possible cooperativity between Nur77 and RXRs, with which the proatherogenic Nor1 does not heterodimerize, 26 has not yet been studied. Although the 3 NR4A isotypes are highly homologous and functionally redundant in artificial transactivation assays, little is known about their relative contribution to macrophage function. NR4As play distinct roles in cellular components of the atherosclerotic plaque, and how the combined and simultaneous activation of these receptors impact on atherosclerosis progression and possibly regression remains to be established. This functional diversity currently clouds the use of NR4As as drug targets in the control of inflammation and atherosclerosis, but also offers a number of exciting possibilities in this field to which these 2 papers have brought significant highlights.
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